The poster argues Mounjaro and Zepbound are getting easier to obtain and that coaches should watch for them on their teams. Only a short excerpt is available.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Investor Steve Wagner says he is uneasy about Novo's Q3, pointing to a Medicare price cut on Ozempic, still its top revenue driver, that began around July 1.
Takashi Miki tells HCPLive the effect didn't need immune iNKT cells, and suggests pairing GLP-1 drugs with PPARα activators for fatty liver disease.
Loading…